{"product_id":"qlgn-vrio-analysis","title":"Qualigen Therapeutics, Inc. (QLGN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Qualigen Therapeutics, Inc. (QLGN)'s potential competitive advantage! This VRIO analysis distills whether its core resources are truly Valuable, Rare, Inimitable, and Organized for sustained market leadership - read on to see the verdict.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eQualigen Therapeutics, Inc. (QLGN) - VRIO Analysis: 1. QN-302 Global Patent Estate\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core intellectual property (IP) for Qualigen Therapeutics, Inc. (QLGN), specifically the patents around their G-quadruplex selective transcription inhibitor, QN-302. Honestly, the IP itself is world-class - protection until \u003cstrong\u003e2040\u003c\/strong\u003e across \u003cstrong\u003e25 countries\u003c\/strong\u003e is a serious moat. But here’s the kicker: the organization is undergoing a massive pivot, evidenced by the recent stockholder approval to rebrand to AIxCrypto Holdings, Inc. (AIXC) in November 2025, following a significant financing led by Faraday Future in September 2025. This shift means the current organizational capacity to drive the QN-302 oncology program might be constrained, even with \u003cstrong\u003e$38.8 million\u003c\/strong\u003e in cash and equivalents as of September 2025. That’s the tension we need to map.\u003c\/p\u003e\n\u003cp\u003eThe QN-302 asset is a G4 binder targeting regulatory regions of cancer genes, which is a distinct mechanism of action versus older agents, especially in hard-to-treat cancers like pancreatic ductal adenocarcinoma (PDAC). The legal protection is ironclad, but the strategic deployment is the question mark. If onboarding takes 14+ days to fully integrate the new AI\/Web3 strategy, the drug development timeline for QN-302 definitely suffers.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on how this IP stacks up using the VRIO framework:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment for QN-302 Patent Estate\u003c\/th\u003e\n\u003cth\u003eCompetitive Implication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProvides exclusive rights to a G-quadruplex selective transcription inhibitor for pancreatic\/GI cancer, potentially yielding massive future royalties or licensing fees.\u003c\/td\u003e\n\u003ctd\u003ePotential for Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePatents secured across \u003cstrong\u003e25 countries\u003c\/strong\u003e, including major markets like Europe, India, China, and Russia, is significant for a company of this size.\u003c\/td\u003e\n\u003ctd\u003eRare Resource\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eImitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh; patent law creates a strong, legally protected barrier to imitation for the product and its manufacturing methods, valid through \u003cstrong\u003e2040\u003c\/strong\u003e.\u003c\/td\u003e\n\u003ctd\u003eDifficult to Imitate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eModerate; the company has secured the patents but the focus has clearly shifted away from maximizing this asset's value following the September 2025 Faraday-led financing and rebranding.\u003c\/td\u003e\n\u003ctd\u003eNot Fully Organized to Exploit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eThe IP is strong, but the current organizational focus on the AI × Web3 strategy limits its immediate exploitation for oncology development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is the opportunity cost. The asset itself is rare and valuable, but the organization isn't currently structured to capture that value through clinical advancement. You have a strong asset that is currently on the back burner while the leadership executes a major strategic pivot.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQN-302 targets regulatory regions of cancer genes.\u003c\/li\u003e\n\u003cli\u003eProtection covers both the drug and its manufacturing.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003e$6.4 million\u003c\/strong\u003e for the nine months ended September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe stock price was \u003cstrong\u003e$3.21\u003c\/strong\u003e as of November 19, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eQualigen Therapeutics, Inc. (QLGN) - VRIO Analysis: 2. Controlling Stake by Faraday Future (FFAI)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Provides immediate, substantial capital infusion - a \u003cstrong\u003e$41 million\u003c\/strong\u003e PIPE financing - and strategic alignment with a major tech\/auto player. The effective price per share for the lead investor was \u003cstrong\u003e$2.246\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eInvestor\u003c\/th\u003e\n\u003cth\u003eInvestment Amount\u003c\/th\u003e\n\u003cth\u003ePro Forma Ownership Percentage\u003c\/th\u003e\n\u003cth\u003eLock-up Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaraday Future (FFAI)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e55%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYT Jia (Personal)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e7%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2-year\u003c\/strong\u003e voluntary lock-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Financing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$41 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFFAI \u0026amp; Affiliates expected to hold over \u003cstrong\u003e62%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Rare; a controlling \u003cstrong\u003e55%\u003c\/strong\u003e direct stake by a major entity like FFAI in a small-cap biotech is highly unusual. Following stockholder approval, FFAI and affiliates are expected to hold approximately \u003cstrong\u003e63%\u003c\/strong\u003e of outstanding common stock.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: High; this is a specific, executed transaction that cannot be easily replicated by competitors. The transaction was completed via a Securities Purchase Agreement for common and preferred stock.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; FFAI executives are taking majority board seats, ensuring deep integration and execution of the new strategy, including a planned rebranding to \u003cstrong\u003eAIxCrypto Holdings, Inc. (NASDAQ: AIXC)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFF will have the right to nominate \u003cstrong\u003e2\u003c\/strong\u003e of the \u003cstrong\u003e5\u003c\/strong\u003e independent directors initially.\u003c\/li\u003e\n\u003cli\u003eFF's nomination rights could increase to \u003cstrong\u003e4\u003c\/strong\u003e of the \u003cstrong\u003e7\u003c\/strong\u003e board seats upon proposal approval.\u003c\/li\u003e\n\u003cli\u003eAppointments include Jerry Wang as Co-CEO and FFAI CFO Koti Meka as QLGN CFO.\u003c\/li\u003e\n\u003cli\u003eYT Jia will serve as Chief Advisor.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained (for now); this relationship is the new core organizational structure and capital base, with a committed \u003cstrong\u003e$30 million\u003c\/strong\u003e market-cap-weighted basket of top \u003cstrong\u003e10\u003c\/strong\u003e crypto assets announced post-financing.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eQualigen Therapeutics, Inc. (QLGN) - VRIO Analysis: 3. C10 Digital Asset Treasury Operation\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Establishes a foothold in the crypto ecosystem, aiming for a core reserve asset anchored by a $30 Million multi-asset allocation announced on October 23, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while crypto treasuries exist, Qualigen Therapeutics’ specific focus on the market-cap-weighted C10 basket (top 10 crypto assets excluding stablecoins) as a core reserve asset is niche.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can initiate a treasury, but replicating the specific product structure involving the partnership with BitGo for institutional-grade custody and OTC execution presents a higher barrier.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this is a primary focus, evidenced by the $30 million commitment to the C10 treasury strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it’s a new venture in a rapidly evolving, competitive space; execution speed is key.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Detail\u003c\/th\u003e\n\u003cth\u003eReference Date\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Treasury Allocation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnnounced October 23, 2025, via partnership with BitGo.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Treasury Allocation\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$10 Million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCompleted prior to the $30 Million announcement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePIPE Financing Secured\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$41 Million\u003c\/strong\u003e total, with \u003cstrong\u003e$30 Million\u003c\/strong\u003e from Faraday Future (FF).\u003c\/td\u003e\n\u003ctd\u003eClosed late September 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFF Ownership Stake\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e55%\u003c\/strong\u003e of common stock on a pro forma basis.\u003c\/td\u003e\n\u003ctd\u003ePost-PIPE financing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price Movement Post-Announcement\u003c\/td\u003e\n\u003ctd\u003eSoared \u003cstrong\u003e83%\u003c\/strong\u003e (pre-market).\u003c\/td\u003e\n\u003ctd\u003eFollowing the $30 Million BitGo deal announcement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe C10 Treasury allocation strategy is structured with defined internal targets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePassive Allocation:\u003c\/strong\u003e \u003cstrong\u003e80%\u003c\/strong\u003e tracking the C10 Index.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eActive Allocation:\u003c\/strong\u003e \u003cstrong\u003e20%\u003c\/strong\u003e guided by a quantitative scoring model.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eQualigen Therapeutics, Inc. (QLGN) - VRIO Analysis: 4. BesTrade DeAI Agent Technology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates a flagship product - a Meta Exchange using AI to optimize transaction pathways, positioning the company in the high-growth AI trading sector.\u003c\/p\u003e\n\u003cp\u003eThe BesTrade DeAI Agent is positioned as the second engine of the Crypto Flywheel, acting as a Meta Exchange to optimize transaction pathways and returns. This initiative is part of a strategic pivot into Web3 and crypto assets, following a rebranding from Qualigen Therapeutics to AIxCrypto, effective November 12, 2025. The company secured a strategic investment of \u003cstrong\u003e$41M\u003c\/strong\u003e from Faraday Future to support this transition.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; AI trading agents are emerging, but Qualigen Therapeutics’ specific architecture is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the underlying AI models are proprietary, but the concept is not entirely novel.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the public beta launch is targeted for the end of November 2025, showing clear development focus.\u003c\/p\u003e\n\u003cp\u003eKey organizational milestones and financial context related to the new strategy include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePublic beta launch of the BesTrade DeAI Agent targeted for the end of \u003cstrong\u003eNovember 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTarget to expand the C10 Treasury to \u003cstrong\u003e$50 Million AUM\u003c\/strong\u003e by the end of \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of October 17, 2025, the C10 Treasury completed \u003cstrong\u003e$12 million\u003c\/strong\u003e in crypto asset allocations.\u003c\/li\u003e\n\u003cli\u003eThe company announced a partnership with BitGo to execute its first multi-asset C10 treasury allocation, committing a \u003cstrong\u003e$30 million\u003c\/strong\u003e market-cap-weighted basket of the top 10 crypto assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; first-mover advantage in a specific niche, but technology evolves fast.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes the VRIO assessment components and relevant associated financial\/statistical data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eFlagship product: BesTrade DeAI Agent (Meta Exchange). Strategic investment of \u003cstrong\u003e$41M\u003c\/strong\u003e secured for this pivot.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eAI trading agents are emerging; specific architecture is proprietary.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eUnderlying AI models are proprietary, but the concept is not entirely novel.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003ePublic beta launch targeted for end of \u003cstrong\u003eNovember 2025\u003c\/strong\u003e. C10 Treasury goal of \u003cstrong\u003e$50 Million AUM\u003c\/strong\u003e by end of \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eFirst-mover advantage in a specific niche, but technology evolves fast.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional relevant financial metrics for the entity (QLGN) as of late 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShare Price as of November 18, 2025: \u003cstrong\u003e$3.21\u003c\/strong\u003e \/ share.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization as of December 8, 2025: \u003cstrong\u003e$9.81 MM\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAverage One-Year Price Target: \u003cstrong\u003e$5.10\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eStock performance noted a surge of \u003cstrong\u003e211.97%\u003c\/strong\u003e on September 22, 2025, amid pivot announcements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eQualigen Therapeutics, Inc. (QLGN) - VRIO Analysis: 5. Phase 1a Clinical Trial Asset (QN-302)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Represents a de-risked, late-stage oncology asset that could still be monetized via licensing or sale, providing a potential biotech safety net. The asset received Orphan Drug Designation from the US FDA for the intended indication of pancreatic cancer in January.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many biotechs have Phase 1 assets, but QN-302’s mechanism as a G-Quadruplex (G4)-selective transcription inhibitor is specific.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the trial data and regulatory filings are unique to the company. Global patents for QN-302 have been granted covering over \u003cstrong\u003e25 countries\u003c\/strong\u003e, with protection extending into \u003cstrong\u003e2040\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low; the company is actively pivoting away, meaning resources dedicated to advancing this are likely minimal. The last 12-month Research \u0026amp; Development Expenses (R\u0026amp;D) were reported as \u003cstrong\u003e$129.5K\u003c\/strong\u003e. The company's Net Income (TTM) was \u003cstrong\u003e-$7.01M\u003c\/strong\u003e, and the Market Cap was \u003cstrong\u003e$6.52M\u003c\/strong\u003e. The company received a deficiency notification from Nasdaq for failure to timely file the Quarterly Report for the period ended March 31, \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; value erodes if development stalls due to lack of focus or funding. The advancement of the Phase 1a trial was funded in part by proceeds received from the divestiture of the Company's diagnostics business in July \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey parameters related to the QN-302 Phase 1a trial and corporate financial context are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDetail\/Amount\u003c\/th\u003e\n\u003cth\u003eSource\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Phase\u003c\/td\u003e\n\u003ctd\u003ePhase 1a (Dose Escalation)\u003c\/td\u003e\n\u003ctd\u003eSafety, Pharmacodynamic, and Pharmacokinetic Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Enrollment (Phase 1a)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e36 patients\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDose escalation portion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Enrollment Completion\u003c\/td\u003e\n\u003ctd\u003eBy end of \u003cstrong\u003e2024\u003c\/strong\u003e (anticipated)\u003c\/td\u003e\n\u003ctd\u003eDosing of at least \u003cstrong\u003e24 patients\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Designation\u003c\/td\u003e\n\u003ctd\u003eOrphan Drug Designation\u003c\/td\u003e\n\u003ctd\u003eFor intended indication of pancreatic cancer (January)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Expiration (Global)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2040\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCovers over \u003cstrong\u003e25 countries\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (LTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$129.5K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest reported figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$7.01M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTrailing Twelve Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe structure of the Phase 1a study includes specific objectives:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTo determine the Maximum Tolerated Dose (MTD) and the dose-limiting toxicities (DLTs) of QN-302 monotherapy in patients with advanced or metastatic solid tumors that have not responded to or have recurred following treatment with available therapies.\u003c\/li\u003e\n\u003cli\u003eTo establish the dose of QN-302 recommended for future studies (the Recommended Phase 2 Dose [RP2D]).\u003c\/li\u003e\n\u003cli\u003eThe dose expansion (Phase 1b) cohort may enroll up to an additional \u003cstrong\u003e20 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eQN-302's mechanism involves selectively stabilizing G4 complexes prevalent in the promoter region of oncogenes, impeding transcription of G4-containing cancer genes. Preclinical data showed QN-302 had significant anti-tumor activity in three patient-derived PDAC patient-derived xenograft models, with survival duration in a KPC genetic mouse model for pancreatic cancer longer than historically shown by gemcitabine.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eQualigen Therapeutics, Inc. (QLGN) - VRIO Analysis: 6. Nasdaq Listing Compliance Mechanism\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Maintained access to public capital markets, crucial for survival, demonstrated by regaining compliance with the \u003cstrong\u003e$2.5 million\u003c\/strong\u003e equity rule via a \u003cstrong\u003e$4.5 million\u003c\/strong\u003e placement in July 2025, and subsequently confirming compliance on \u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e, following a \u003cstrong\u003e$41 million\u003c\/strong\u003e PIPE financing.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many public companies manage compliance, but Qualigen Therapeutics’ recent struggle, including reporting negative stockholders' equity of approximately \u003cstrong\u003e$1.6 million\u003c\/strong\u003e as of June 30, 2025, makes this a hard-won capability.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; it’s a regulatory process, not a unique skill, but the recent success in securing multiple capital infusions to meet deadlines is a positive data point.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the management team successfully executed the necessary financing and plan submissions, including filing the Q1 2025 10-Q by the \u003cstrong\u003eJuly 21, 2025\u003c\/strong\u003e deadline and closing the \u003cstrong\u003e$4.5 million\u003c\/strong\u003e placement by \u003cstrong\u003eJuly 28, 2025\u003c\/strong\u003e, and later the \u003cstrong\u003e$41 million\u003c\/strong\u003e PIPE by \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; this is table stakes for a listed company, though the ability to secure capital under duress temporarily mitigates immediate delisting risk.\u003c\/p\u003e\n\n\u003cp\u003eThe mechanism's recent activity involved several critical financial and regulatory milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial non-compliance notice received on \u003cstrong\u003eJuly 23, 2025\u003c\/strong\u003e, for falling below the \u003cstrong\u003e$2.5 million\u003c\/strong\u003e stockholders' equity requirement (Rule 5550(b)(1)).\u003c\/li\u003e\n\u003cli\u003eRegained initial compliance through a \u003cstrong\u003e$4.5 million\u003c\/strong\u003e private placement of Series A-3 Preferred Stock, closing by \u003cstrong\u003eJuly 28, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSubmitted a compliance maintenance plan to Nasdaq, accepted for a \u003cstrong\u003e12-month\u003c\/strong\u003e period initially.\u003c\/li\u003e\n\u003cli\u003eSuccessfully regained compliance with Listing Rule 5250(c)(1) (Periodic Filing Rule) by filing the Q1 2025 10-Q by \u003cstrong\u003eJuly 21, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSubsequent confirmation of compliance with the Equity Rule 5550(b)(1) was received from Nasdaq on \u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e, following a \u003cstrong\u003e$41 million\u003c\/strong\u003e PIPE financing.\u003c\/li\u003e\n\u003cli\u003eThe company will remain subject to a \u003cstrong\u003eone-year Panel Monitor\u003c\/strong\u003e period as of the \u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e notice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eKey Financial and Compliance Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Status\u003c\/td\u003e\n\u003ctd\u003eDate\/Rule Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum Stockholders' Equity Requirement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNasdaq Rule 5550(b)(1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Equity Below Threshold\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e-$1.6 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Remedial Financing Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeries A-3 Preferred Stock Placement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubsequent Major Financing Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$41 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePIPE Financing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Compliance Deadline Met\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJuly 28, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the $2.5M equity rule\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinal Compliance Confirmation Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 19, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor Rule 5550(b)(1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Monitoring Status\u003c\/td\u003e\n\u003ctd\u003eSubject to \u003cstrong\u003eone-year Panel Monitor\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of November 19, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eQualigen Therapeutics, Inc. (QLGN) - VRIO Analysis: 7. EAI RWA Utility Token Whitepaper Development\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Signals intent to build a sustainable on-chain value system by defining tokenomics and Real World Asset (RWA) integration, supported by the C10 Treasury targets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; RWA tokens are a growing trend, but having a defined whitepaper ready for release is a step ahead.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the specific tokenomics tied to the C10 ecosystem are proprietary.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the whitepaper release is tied to the November 12, 2025 rebranding event to AIxCrypto.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; depends entirely on market acceptance and regulatory clarity for utility tokens.\u003c\/p\u003e\n\u003cp\u003eThe strategic roadmap for the EAI RWA Utility Token is linked to the following quantitative milestones and statuses:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRebranding to AIxCrypto scheduled for November 12, 2025.\u003c\/li\u003e\n\u003cli\u003eEAI RWA Utility Token Whitepaper release targeted by the end of November 2025.\u003c\/li\u003e\n\u003cli\u003eTargeted C10 Treasury Assets Under Management (AUM) by end of 2025: $50 Million.\u003c\/li\u003e\n\u003cli\u003eC10 Treasury crypto asset allocations as of October 17, 2025: $12 million.\u003c\/li\u003e\n\u003cli\u003eCommitted allocation to a market-cap-weighted C10 crypto basket (excluding stablecoins) on October 23, 2025: $30 million.\u003c\/li\u003e\n\u003cli\u003eUnrealized gain on approximately $10 million in C10 Treasury allocations as of September 18, 2025: approximately 7%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe following table provides context on the C10 Treasury component relative to the company's broader financial position as of late 2024:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eC10 Treasury Target AUM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e12\/31\/2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e12\/31\/2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccumulated Deficit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$123 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eQualigen Therapeutics, Inc. (QLGN) - VRIO Analysis: 8. Marizyme Co-Development Agreement\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a potential, non-dilutive revenue stream from the commercialization of DuraGraft™, including up to \u003cstrong\u003e$1,500,000\u003c\/strong\u003e in funding payments for post-clearance clinical studies and launch assistance, plus a \u003cstrong\u003e$200,000\u003c\/strong\u003e exclusivity fee paid by Qualigen for a negotiation period ending May 31, 2024. Qualigen earns a portion of Net Sales, up to a cumulative total equal to a \u003cstrong\u003e2X\u003c\/strong\u003e return on invested capital.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; a co-development deal in a separate medical field offers diversification into the market for DuraGraft™, which received De Novo FDA Clearance on October 4, 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; this is a signed, specific contract, the Co-Development Agreement, dated April 11, 2024, with Marizyme, Inc..\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the agreement exists, but its execution success is tied to Marizyme’s efforts, not Qualigen Therapeutics’ primary focus, although subsequent financial arrangements show deeper integration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it’s a passive asset unless actively managed for milestones, though subsequent lending activity suggests a more active financial involvement.\u003c\/p\u003e\n\u003cp\u003eThe financial relationship has evolved beyond the initial co-development terms, as evidenced by subsequent secured lending:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003eInitial Co-Development Funding (Qualigen to Marizyme)\u003c\/td\u003e\n\u003ctd\u003eSubsequent Secured Note (As of September 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrincipal Amount\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1,500,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4,526,462.18\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest Rate\u003c\/td\u003e\n\u003ctd\u003eReturn tied to Net Sales (up to 2X investment)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e18%\u003c\/strong\u003e per annum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Date\/Term\u003c\/td\u003e\n\u003ctd\u003eExclusivity Period ended May 31, 2024\u003c\/td\u003e\n\u003ctd\u003eMaturity Date: August 21, 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eDuraGraft targets the Coronary Artery Bypass Grafting (CABG) market, which is valued at \u003cstrong\u003e$10 Billion\u003c\/strong\u003e, addressing significant clinical issues:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSaphenous vein graft failure rates reach \u003cstrong\u003e20-40%\u003c\/strong\u003e within the first year post-CABG surgery.\u003c\/li\u003e\n\u003cli\u003eApproximately \u003cstrong\u003e50%\u003c\/strong\u003e of saphenous vein grafts fail within 5-10 years.\u003c\/li\u003e\n\u003cli\u003eDuraGraft aims to prevent oxidative damage and slow the progression of vein graft failure, potentially reducing repeat procedures and hospital stays.\u003c\/li\u003e\n\u003cli\u003eThere are over \u003cstrong\u003e500,000\u003c\/strong\u003e annual CABG surgeries in the US.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe financial commitment has increased significantly through lending, with the amended principal balance reaching \u003cstrong\u003e$4,526,462.18\u003c\/strong\u003e by September 2025, secured by a security interest in substantially all of Marizyme's assets. This latest principal amount exceeds Qualigen Therapeutics' market capitalization of under \u003cstrong\u003e$3 million\u003c\/strong\u003e as of July 2024.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eQualigen Therapeutics, Inc. (QLGN) - VRIO Analysis: 9. Corporate Transformation Agility\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The demonstrated ability to execute a radical, rapid pivot from a traditional biotech to a Web3\/AI entity within months. This transformation is supported by the $41 million Private Investment in Public Equity (PIPE) financing, led by Faraday Future Intelligent Electric Inc. (FFAI).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; such a complete overhaul, including rebranding to AIxCrypto Holdings, Inc. (AIXC) and major shareholder change, is rare for a public company. The transaction involved the issuance of 337,432 shares of common stock and 39,943 shares of Series B convertible preferred stock as part of the $41,000,000 Offering.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; this required specific deal-making with Faraday Future, which invested $30 million, and internal restructuring confirmed by stockholder vote. The company also secured $4.5 million via a private placement of Series A-3 Preferred Stock to regain Nasdaq compliance, which previously failed the $2.5 million stockholders' equity requirement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the stockholder vote confirmed majority approval for governance changes, with Faraday Future expected to hold an estimated 55% direct equity ownership (approximately 63% including affiliates like YT Jia, who invested approximately $4 million). The Nasdaq ceremony on November 20 confirms organizational alignment on this new path.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (as a strategic mindset); this signals a management team willing to take bold, high-risk\/high-reward strategic swings. The company reported a net loss of $2.0 million for the quarter and $6.4 million for the nine months ended September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e Draft the pro forma balance sheet reflecting the $41 million PIPE and the $4.5 million compliance placement by next Tuesday.\u003c\/p\u003e\n\u003cp\u003eThe financing events significantly altered the balance sheet structure:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eBalance Sheet Item\u003c\/td\u003e\n\u003ctd\u003ePre-Financing Context (YE 2024)\u003c\/td\u003e\n\u003ctd\u003eFinancing Impact Summary\u003c\/td\u003e\n\u003ctd\u003ePost-Financing (As of Sept 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e$4.7 million (Total Assets)\u003c\/td\u003e\n\u003ctd\u003eIncrease from $41.0M PIPE and $4.5M Placement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNet increase after funding operations\/debt repayment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Equity\u003c\/td\u003e\n\u003ctd\u003e(Reflected in YE 2024 Assets)\u003c\/td\u003e\n\u003ctd\u003eIncrease by $41.0 million (PIPE) + $4.5 million (Placement)\u003c\/td\u003e\n\u003ctd\u003e(Implied by Asset Increase)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company plans to use up to $6,800,000 of net cash proceeds from the $41.0 million Subscription Agreement to pay existing debt and fund current operations.\u003c\/p\u003e\n\u003cp\u003eKey operational and strategic financial metrics post-transformation announcement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe effective price for the $41 million PIPE investment was \u003cstrong\u003e$2.246\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eThe company's market capitalization was approximately \u003cstrong\u003e$9.12 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company's Price to Earnings Ratio is \u003cstrong\u003e-0.30\u003c\/strong\u003e, indicating negative earnings.\u003c\/li\u003e\n\u003cli\u003eThe company has secured multiple patents for its cancer drug QN-302 across \u003cstrong\u003e25\u003c\/strong\u003e countries.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516237570197,"sku":"qlgn-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/qlgn-vrio-analysis.png?v=1740208819","url":"https:\/\/dcf-model.com\/fr\/products\/qlgn-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}